The drugs at the center of a federal case were not ordinary retail products. They included expensive cold-chain treatments used for cancer, macular degeneration and autoimmune disease. A wholesale distributor’s former operations manager has now received 30 months in prison for helping obtain more than $47.7 million in prescription medicines under false representations and resell them for profit.
The sentence followed a conspiracy guilty plea
Frank Incognito, 46, was sentenced July 29, and the Justice Department announced the result August 4. He had pleaded guilty to conspiring to unlawfully resell medications purchased through health-care entities.
The District of New Jersey’s live release says the scheme ran from roughly June 2012 through January 2019. Doctors’ practices bought medications after representing that the products would treat their own patients and would not be redistributed. Prosecutors say none of the drugs were used for those doctors’ patients and instead went to customers of the wholesale businesses.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers scams, benefits, and money many retirees may be owed, a couple times a week. Subscribe free.
Restricted purchasing terms were part of the price
A manufacturer or authorized distributor may sell medicine to a medical practice on the understanding that the practice will administer it to its own patients. The restriction can govern eligibility, handling and distribution. A buyer who conceals an intent to resell is not merely finding a lower price; prosecutors said the false representation was how the product was obtained.
The medicines described in the case were primarily biologic infusion products requiring controlled storage. That makes custody financially important. A payer, provider or patient may assume the product followed an authorized path with documented temperature and ownership changes. Diversion inserts an undisclosed transaction into that chain.
Older patients often face substantial coinsurance or coverage decisions around infused drugs. The case does not say patients who received any specific product were harmed or personally overcharged. Its money relevance lies in the integrity of a market where acquisition source, handling and billing status can affect what providers pay and what plans reimburse.
Drug tracing is designed to preserve an authorized chain
The Food and Drug Administration’s Drug Supply Chain Security Act resources describe an electronic, interoperable system for identifying and tracing certain prescription drugs as they move through the United States. Transaction records help trading partners investigate suspect products and determine where a package entered the chain.
Tracing is different from proving that a medicine is clinically effective for one patient. It answers supply questions: who sold it, who received it, whether the parties were authorized and whether the identifier matches the product. Those controls protect expensive therapies from substitution and diversion.
A patient cannot audit a wholesale chain personally, but can use a licensed pharmacy or established infusion provider and retain the explanation of benefits. An offer to sell a normally supervised infusion drug directly at a steep discount deserves independent confirmation from a physician or pharmacist.
Unexpected packaging or sellers call for verification
The FDA’s official counterfeit-medicine guidance advises consumers to look for changes in packaging, appearance and effect and to obtain prescription products through licensed sources. Counterfeit products are not alleged in this sentencing release, but the protective principle is related: provenance matters when a medicine leaves an authorized channel.
A lower price alone does not establish fraud. Assistance programs, negotiated plan prices and legitimate specialty pharmacies can reduce cost. The concern is a seller who cannot be verified, refuses to identify the dispensing pharmacy or asks for payment outside normal medical billing.
Statements should identify the provider, drug and service date. If those details do not match treatment received, the patient can contact the provider and plan in writing. A prompt correction can protect both medical records and benefit dollars without assuming criminal conduct.
The $47.7 million describes product flow, not patient restitution
The announced amount reflects drugs bought and sold during the conspiracy. The release does not create a claim fund for people treated with the medicines, and the 30-month term applies to the manager whose sentence was announced, not every person associated with the transactions.
The government’s account ends with a custody lesson relevant to retirement health spending. High-cost medicines carry value at every step from manufacturer to patient. Documentation of that path is not paperwork added after the medicine; it is part of what allows patients, plans and providers to trust what they are paying for.
For refrigerated biologics, custody includes storage as well as ownership. Lot numbers, expiration dates and temperature controls help a pharmacy or infusion center determine whether a package remained suitable for use. A patient who sees damaged packaging or an unfamiliar label should preserve the container and contact the dispensing professional rather than attempting to authenticate a high-cost drug through an online seller.
Explanation-of-benefits records can reveal a second mismatch: a drug quantity or administration date that does not match the appointment. Asking the provider to reconcile the claim protects the patient’s benefit history and may prevent coinsurance from being calculated on a service that was not delivered. The inquiry should identify the exact line item while leaving clinical judgments to the treating team.
The criminal case involved false purchasing representations and resale, not a finding that every unit was counterfeit or medically defective. Keeping that boundary clear matters for patients who received legitimate treatment and might otherwise stop therapy out of fear. Questions about a specific dose belong with the licensed provider and product records, not with conclusions drawn from the size of the prosecution.
This article was researched and drafted with AI assistance and reviewed against the linked primary sources.
More Financial Reading
- Bank statements: how long to keep them and when to toss them
- The ideal retirement withdrawal rate so your savings actually last
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
